This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Wall Street Analysts Are Bullish on Top Healthcare Picks

Tipranks - Tipranks - Sat Jun 13, 7:56AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Genmab (GMAB), HCA Healthcare (HCA) and Thermo Fisher (TMO) with bullish sentiments.

Introducing TipRanks MCP for Agents

Genmab (GMAB)

Truist Financial analyst Gregory Renza maintained a Buy rating on Genmab today. The company’s shares closed last Thursday at $25.24.

According to TipRanks.com, Renza is a 5-star analyst with an average return of 15.0% and a 46.2% success rate. Renza covers the Healthcare sector, focusing on stocks such as Ascentage Pharma Group International Unsponsored ADR, Perspective Therapeutics, and Abivax SA Sponsored ADR. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Genmab with a $35.07 average price target, which is a 40.5% upside from current levels. In a report issued on June 1, Wells Fargo also assigned a Buy rating to the stock with a $40.00 price target.

See today’s best-performing stocks on TipRanks >>

HCA Healthcare (HCA)

In a report released yesterday, Scott Fidel from Goldman Sachs maintained a Buy rating on HCA Healthcare, with a price target of $558.00. The company’s shares closed last Thursday at $378.51.

According to TipRanks.com, Fidel is a 4-star analyst with an average return of 7.6% and a 64.3% success rate. Fidel covers the Healthcare sector, focusing on stocks such as Concentra Group Holdings Parent, Inc., BrightSpring Health Services, Inc., and Ardent Health Partners, Inc. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for HCA Healthcare with a $493.92 average price target, implying a 31.7% upside from current levels. In a report issued on May 31, TipRanks – PerPlexity also upgraded the stock to Buy with a $428.00 price target.

Thermo Fisher (TMO)

William Blair analyst Matt Larew reiterated a Buy rating on Thermo Fisher today. The company’s shares closed last Thursday at $475.66.

According to TipRanks.com, Larew is a 3-star analyst with an average return of 2.1% and a 48.8% success rate. Larew covers the Healthcare sector, focusing on stocks such as Maravai Lifesciences Holdings, West Pharmaceutical Services, and Ginkgo Bioworks Holdings. ;'>

Thermo Fisher has an analyst consensus of Strong Buy, with a price target consensus of $594.94, which is a 22.9% upside from current levels. In a report issued on June 1, Wolfe Research also initiated coverage with a Buy rating on the stock with a $535.00 price target.

Read More on GMAB:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).